Please see below all current lung cancer clinical trials of the Central Coast Cancer Centre.
Name: Relativity CA 224-104
A study to evaluate the safety and effectiveness of combining trial anticancer drugs with chemotherapy, in people with non-small cell lung cancer.
Principal Investigator: Dr Matthew Chan
Study Coordinator: Michelle Dixon
Status: Temporarily on hold
Condition: Lung Cancer
More information about Relativity CA 224-104
Name: DREAM3R
A phase 3 Randomised trial DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma.
Principal Investigator: Dr Matthew Chan
Study Coordinator: Michelle Dixon
Status: Recruiting
Condition: Lung Cancer- Mesothelioma
More information about DREAM3R
Name: CA209-73L
A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab Plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
Principal Investigator: Dr Matthew Chan
Study Coordinator: Cassandra Rubio
Status: Recruiting
Condition: Lung Cancer
More information about CA209-73L
Name: SGNLV-005
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for unresectable locally advanced metastatic solid tumours.
Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Closed
Condition: Lung Cancer
More information about SGNLV-005
Name: PACIFIC 9
Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy.
Principal Investigator: Dr Matthew Chan
Study Coordinator: Michelle Dixon
Status: Open
Condition: Lung Cancer
More information about PACIFIC 9
Name: LAGOON
A Randomised, Multicentre, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) In Relapsed Small Cell Lung Cancer (SCLC) patients. LAGOON.
Principal Investigator: Dr Matthew Wong
Study Coordinator: Michelle Dixon
Status: Open
Condition: Lung Cancer
More information about LAGOON
Name: HLX10-020-SCLC302
A randomised, double-blind, International Multicentre, Phase III Study to evaluate the Efficacy and safety of HLX10 in combination with Chemotherapy and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer.
Principal Investigator: Dr Matthew Chan
Study Coordinator: Cassandra Rubio
Status: Open
Condition: Small Cell Lung Cancer
More information about HLX10-020-SCLC302
More information
For more information about medical oncology clinical trials please contact the Nurse Unit Manager on 02 4320 9890 or see:
Research and Clinical Trials